Peritoneal mesothelioma: lines of therapy
4 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | Fit | Unfit / older |
|---|---|---|---|
| Screening, prevention and diagnosis | 1 | · | · |
| Early / localised | 1 | 1 | · |
| Special situations | · | · | 1 |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis | CT, laparoscopy with biopsy and scoring of disease extent; germline BAP1 testing when young or with a family history. | - |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Indolent variants | Well-differentiated papillary and multicystic tumours: surgical removal and surveillance; systemic therapy rarely needed. | 63 | ||
| Fit | Resectable epithelioid disease, fit patient | Cytoreductive surgery with HIPEC in an experienced centre; long-term survival in a substantial fraction. | 78 |
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Unfit / older | Unresectable or unfit | Platinum-pemetrexed chemotherapy; nivolumab plus ipilimumab or pembrolizumab combinations extrapolated from pleural trials and small peritoneal series. | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.